Chinese drug maker Jilin Zixin Pharmaceutical Industrial Co., Ltd. has agreed to invest US$42 million in Nabsys 2.0, a U.S. high definition genome mapping firm. Zixin Pharmaceutical plans to initially invest US$6 million or its RMB equivalent, then contribute around US$36 million or its RMB equivalent to acquire 67% of Nabsys 2.0, which means the […]

Visit ChinaMoneyNetwork.com for more daily finance news, including audio and video Internet podcasts covering important investment news and financial events in China. Follow us on Twitter @chinamoneypod subscribe to all episodes on iTunes.